Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome

To evaluate the clinical efficacy and safety of baminercept, a lymphotoxin β receptor IgG fusion protein (LTβR‐Ig), for the treatment of primary Sjögren's syndrome (SS), and to explore the possible mechanisms of action of this treatment.

[1]  H. Moutsopoulos,et al.  Sjögren's syndrome. , 2019, Annual review of pathology.

[2]  R. Moots,et al.  Randomized Controlled Trial of Rituximab and Cost‐Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome , 2017, Arthritis & rheumatology.

[3]  Wei Zhang,et al.  Identification of Novel CD4+ T Cell Subsets in the Target Tissue of Sjögren’s Syndrome and Their Differential Regulation by the Lymphotoxin/LIGHT Signaling Axis , 2016, The Journal of Immunology.

[4]  A. Tzioufas,et al.  Clinical picture, outcome and predictive factors of lymphoma in Sjӧgren syndrome. , 2015, Autoimmunity reviews.

[5]  I. Sanz,et al.  Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response , 2015, PloS one.

[6]  Philippe Ravaud,et al.  EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide , 2015, RMD Open.

[7]  Xavier Mariette,et al.  Sjögren Syndrome‐associated lymphomas: an update on pathogenesis and management , 2015, British journal of haematology.

[8]  H. Ueno,et al.  Pathophysiology of T follicular helper cells in humans and mice , 2015, Nature Immunology.

[9]  G. Baron,et al.  Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI) , 2014, Annals of the rheumatic diseases.

[10]  J. Bienkowska,et al.  Lymphotoxin-LIGHT Pathway Regulates the Interferon Signature in Rheumatoid Arthritis , 2014, PloS one.

[11]  M. Iadarola,et al.  Primary Sjögren's Syndrome Is Characterized by Distinct Phenotypic and Transcriptional Profiles of IgD+ Unswitched Memory B Cells , 2014, Arthritis & rheumatology.

[12]  J. Guthridge,et al.  Proinflammatory Adaptive Cytokine and Shed Tumor Necrosis Factor Receptor Levels Are Elevated Preceding Systemic Lupus Erythematosus Disease Flare , 2014, Arthritis & rheumatology.

[13]  Simon A. Jones,et al.  Ectopic lymphoid-like structures in infection, cancer and autoimmunity , 2014, Nature Reviews Immunology.

[14]  X. Mariette,et al.  Treatment of Primary Sjgren Syndrome With Rituximab , 2014, Annals of Internal Medicine.

[15]  P. Gaffney,et al.  Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren’s syndrome , 2013, Nature Genetics.

[16]  S. McColl,et al.  A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. , 2013, Cytokine & growth factor reviews.

[17]  E. L. Prak,et al.  Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. , 2013, Arthritis and rheumatism.

[18]  E. Meffre,et al.  Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation. , 2013, Arthritis and rheumatism.

[19]  Thomas Gebhardt,et al.  Memory T cell subsets, migration patterns, and tissue residence. , 2013, Annual review of immunology.

[20]  John C. Davis,et al.  Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial , 2012, Arthritis Research & Therapy.

[21]  A. Bolstad,et al.  Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome , 2011, Arthritis research & therapy.

[22]  E. Dejardin,et al.  Biology and signal transduction pathways of the Lymphotoxin-αβ/LTβR system. , 2011, Cytokine & growth factor reviews.

[23]  R. Kaaks,et al.  Validity of multiplex-based assays for cytokine measurements in serum and plasma from "non-diseased" subjects: comparison with ELISA. , 2009, Journal of immunological methods.

[24]  A. Bolstad,et al.  Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren's syndrome in salivary glands of non-obese diabetic mice , 2009, Arthritis research & therapy.

[25]  J. Browning.  Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease , 2008, Immunological reviews.

[26]  G. Valesini,et al.  CXCL13, CCL21, and CXCL12 Expression in Salivary Glands of Patients with Sjögren’s Syndrome and MALT Lymphoma: Association with Reactive and Malignant Areas of Lymphoid Organization1 , 2008, The Journal of Immunology.

[27]  S. Perrin,et al.  Lymphotoxin-β Receptor Signaling Is Required for the Homeostatic Control of HEV Differentiation and Function , 2005 .

[28]  G. Valesini,et al.  Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome. , 2005, Arthritis and rheumatism.

[29]  P. Lipsky,et al.  Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. , 2004, Arthritis and rheumatism.

[30]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[31]  M. García-Carrasco,et al.  Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren's syndrome. Correlation with clinical, immunological and histological features. , 2002, Rheumatology.

[32]  R. Jonsson,et al.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.

[33]  J. Natvig,et al.  Bm1–Bm5 Classification of Peripheral Blood B Cells Reveals Circulating Germinal Center Founder Cells in Healthy Individuals and Disturbance in the B Cell Subpopulations in Patients with Primary Sjögren’s Syndrome1 , 2001, The Journal of Immunology.

[34]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[35]  M. Lemp.  Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. , 1995, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.

[36]  J. Pers,et al.  BAFF-induced changes in B cell antigen receptor-containing lipid rafts in Sjögren's syndrome. , 2006, Arthritis and rheumatism.